Actively Recruiting
2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD
Led by University of Maryland, Baltimore · Updated on 2026-02-03
150
Participants Needed
1
Research Sites
296 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluate and study the immunologic changes to the ocular surface in cancer patients.
CONDITIONS
Official Title
2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients (≥ 18 years of age) who visit the Eye clinic either in the UMGCCC within the UMD Hospital or the UMD Faculty Physicians Ophthalmology Practice at the UMD Professional Building or satellite locations for initial visits or established visits.
- The patient must be able to understand and sign and date the informed consent form approved by the IRB.
You will not qualify if you...
- Vulnerable populations: neonates, children, prisoners, institutionalized individuals.
- Inability or refusal to provide informed consent.
- History of ocular surgery (except refractive surgery or cataract surgery)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Geenebaum Cancer Center, University of Maryland Medical Center
Baltimore, Maryland, United States, 21201
Actively Recruiting
Research Team
S
Sarah B Sunshine, MD
CONTACT
P
Patricia Lesho
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here